Market Intelligence, Clinical Progress, and High-Purity Reagents for Neurological & Cardiac Channelopathy Development.
1. Introduction
ANK3 (Ankyrin-3/Ankyrin-G) is a master scaffolding protein that organizes voltage-gated ion channels and cell adhesion molecules at specialized membrane domains, including the axon initial segment (AIS) in neurons and the intercalated discs in cardiomyocytes. It functions as a critical node in neuronal architecture and cardiac electrophysiology, making it a high-value target for CNS disorders (bipolar disorder, ASD, schizophrenia) and inherited arrhythmia syndromes (Brugada syndrome, Long QT syndrome). ANK3 contains multiple functional domains: ankyrin repeats (MBD), spectrin-binding domain (SBD), ZU5 domains (ZU5 1 and ZU5 2), and a Death domain, enabling diverse protein-protein interactions.
2. TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ANK3 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANK3 Recombinant Domain Proteins: MBD, SBD, ZU5 1/2, Death Domain; also Ankyrin Repeat Domain (1263-1420 aa). High purity (>95%), Endotoxin <1 EU/ug. Sequence Verified. | View ANK3 Products |
| Gene Delivery | ANK3 Lentivirus Premade Particles (full-length ORF, isoform 1/2). High titer (>10^8 TU/ml) for stable cell line construction in iPSC-cardiomyocytes or neuronal models. | View ANK3 Products |
| Benchmark Ab | Anti-ANK3 Recombinant Monoclonal Antibody. Sequence-defined positive control for Western blot, ICC, and Co-IP. | View ANK3 Products |
| Validator | ANK3 siRNA Set (3 unique sequences). For knockdown verification and assay specificity controls. | View ANK3 Products |
| Related Target A | SCN5A (Nav1.5) – Voltage-gated sodium channel; essential for cardiac co-localization assays. | View SCN5A Products |
| Related Target B | ANK2 (Ankyrin-B) – Paralog scaffolding protein; critical counter-screen for isoform-specificity studies. | View ANK2 Products |
| Related Target C | SCN2A (Nav1.2) – Sodium channel interacting with ANK3 at the AIS. | View SCN2A Products |
| Related Target D | NFASC (Neurofascin) – Structural partner for nodal assembly. | View NFASC Products |
| Related Target E | KCNQ1 (KV7.1) – Component of IKs channel complex organized by ANK3. | View KCNQ1 Products |
| Related Target F | CACNA1C (Cav1.2) – L-type calcium channel regulated by ANK3 scaffolding. | View CACNA1C Products |
3. Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Large multi-domain architecture prevents full-length soluble purification (190 kDa full-length) | Defined domain fragments (MBD, SBD, ZU5 1/2, Death Domain) with >95% purity and verified N-terminus. Suitable for SPR, BLI, X-ray crystallography, and Cryo-EM. |
| Intracellular PPI validation requires native folding context | HEK293-expressed ANK3 Lentivirus for stable cell lines preserving native phosphorylation patterns. |
| Paralog cross-reactivity (ANK1/ANK2) | Isoform-specific immunogens selected from divergent insertion domains; Sequence Verified with <15% paralog homology in epitope region. |
| Disease model fidelity (Brugada, Bipolar Disorder) | Mutant recombinant proteins (disease-associated variants, e.g., ANK3 mutations found in patients) with exact amino acid substitution and endotoxin control. |
| Knockdown validation in neural models | Pre-verified siRNA sets for reliable transcript reduction; parallel controls for SCN5A, KCNQ1 to confirm scaffold-specific phenotypes. |
| False Positives in PPI assays | Sequence-verified domain truncations eliminate non-specific binding artifacts. |
4. Live ANK3 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
5. Global Clinical Landscape & Future Outlook
The ANK3 therapeutic landscape is currently concentrated in preclinical and translational research, driven by robust human genetic evidence linking ANK3 variants to bipolar disorder, autism spectrum disorder, schizophrenia, and cardiac channelopathies including Brugada syndrome and Long QT syndrome. As the field pivots from symptomatic management to precision genetic interventions, dominant modalities include AAV-mediated gene supplementation for cardiac isoforms, small-molecule stabilizers of protein-protein interactions at the axon initial segment (e.g., targeting spectrin-binding or ankyrin repeat domains), antisense oligonucleotides (ASOs) for haploinsufficiency-related CNS disorders, and emerging targeted protein degraders (PROTACs) for precision neuroscience. The next wave of R&D will prioritize isoform-selective engagement to avoid disrupting erythroid (ANK1) or generalized membrane scaffolding (ANK2) functions.
6. Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (AAV-ANK3) | Academic consortia & early-stage gene therapy biotechs | Brugada Syndrome, Long QT Syndrome, Arrhythmogenic Cardiomyopathy | Functional rescue assays using ANK3 Lentivirus in iPSC-cardiomyocytes |
| Small Molecule PPI Modulators | CNS-focused biotechs & academic consortia | Bipolar Disorder, Cardiac Arrhythmia, Schizophrenia | SPR/BLI with purified ANK3 MBD/SBD domains (>95% purity, verified sequence) for target engagement |
| ASO / Splice Modulators | Ionis, Praxis Precision Medicines, neuroscience platforms | Bipolar Disorder, Autism Spectrum Disorder | Isoform-specific knockdown validation with ANK3 siRNA sets and mutant validation panels |
| PROTACs (Targeted Protein Degradation) | Emerging TPD companies | Precision Neuroscience | Degradation & ligand binding assays using specific antibodies and purified antigens |